IMMUNO-ONCOLOGY XCHANGE
EUROPE 2023
Zurich, November 21

Welcome to hubXchange’s Europe Immuno-Oncology Xchange 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions. 
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, Cell Therapies and Next-Generation Therapies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland

SNAPSHOTS OF DISCUSSION TOPICS

  • Predictive biomarkers for IO treatment used in clinical practice now and in the future
  • The rise of spatial omics technologies and their potential for new biomarker discovery
  • Selecting humanized mouse models for efficacy studies in immuno-oncology
  • In vivo/ ex vivo models for development of immuno-oncology drugs

Regulatory and market access evolution and impact on fast-to-market development strategies

TME-targeting combinations – improving efficacy

Overcoming resistance of poorly sensitive tumors to immunotherapy through orthogonal approaches

Full Xchange Agenda

Click on each track for detailed agenda

Immune Biomarkers

Time
Titles and Bullets
Facilitator
8:00 – 8:30
Registration 
08:30 – 09:10

Opening Address & Keynote Presentation by Synexa

The Search for Immunological Beauty

The immune system elegantly strives to control and balance the interplay of flexibility and robustness in the interaction of an organism with its environment. Scientific understanding and appreciation of the coordinated biological complexity of the immune system is expanding on a daily basis. This growth has been paralleled by our ability to harness the power of the immune system for the development of therapeutic interventions. Subjectively we may describe the immune system as “a thing of beauty” in our attempts to abstract, acknowledge and to some degree comprehend the enormity of its intricacies. There is however merit in exploring alternative views to define and quantify immunological beauty as a means of generating fresh insights into the fundamental organization of the immune system which in turn will likely impact our ability to develop and better monitor immunotherapies.

Justin Devine is a medical doctor, immunologist, pharmacologist (Stellenbosch University) and a co-founder of Synexa. Currently operating as Chief Innovation Officer, his primary focus is to understand clients’ objectives in new drug development by designing biomarker strategies to bring real insight to the challenges of clinical development. Justin has a very deep understanding of the role that biomarkers and pharmacogenetics play in understanding the performance of a candidate drug. He is particularly passionate about improving the drug development process by bringing innovative approaches to early phase research, including new ideas in translational medicine, bioinformatics and artificial intelligence.

Justin Devine web
9:15 – 10:15

Predictive biomarkers for IO treatment used in clinical practice now and in the future

  • What are the challenges and limitations of IO predictive Biomarkers currently used in clinical practice?
  • Which new promising IO predictive biomarkers can we expect in the next future?
  • How can we improve the predictive value of IO biomarkers?
  • Which predictive biomarkers could support IO combinations?

Dr Serafino Pantano has more than 15 years of experience in pharma and biotech, mainly spent working on Clinical Biomarkers in Oncology. Since January 2021 he is heading ADC Therapeutics Clinical Biomarker Development. Before ADCT Dr. Pantano was Biomarker and Diagnostics Regional Director Medical Affairs in MSD, working on Pembrolizumab and Olaparib. Prior to MSD he was Precision Medicine Director in Novartis Oncology, working on the ALK inhibitor ceritinib, and on IO assets, including CTL019. Earlier in his career Dr. Pantano was Group Leader in Roche and prior to that he was Lab Head in Novartis

10:20 – 10:50
1-2-1 Meetings/Networking Break
10:55 – 11:25
1-2-1 Meetings/Networking Break
11:30 – 11:40
Morning Refreshments
11:40 – 12:40
Challenges in Immunotherapy: efficiently translating immune biomarkers from discovery to deployment
  • Utility of current spatial biology technologies 
  • Limitations to overcome: assay and workflow standardization and image analysis
  • Validation required for assay implementation

Dr. Angela Vasaturo is a Director of Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. In 2012, Angela was among the first postdocs in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, digital pathology, spatial biology and tissue imaging.

Angela Vasaturo
12:40 – 13:40
Networking Lunch
13:45 – 14:15

1-2-1 Meetings/Networking Break

14:20 – 14:55
1-2-1 Meetings/Networking Break
15:00 – 16:00

The rise of spatial omics technologies and their potential for new biomarker discovery

Celine Pallaud is an established senior leader with a Ph.D. in genetics and 20+ years of Pharma experience with strong leadership capabilities, results-oriented, and conveys a sense of urgency and drives for closure. Celeine has led several franchises in the personalized medicine arena across multiple therapeutic areas along the drug development value chain.
Celine has a deep understanding of pharmaceutical development, stakeholder management including regulators and business operations. She has an extraordinary perspective in leveraging innovative approaches to expedite drug development and address the complexities of emerging data.
Celine has an in depth experience in diagnostic device development aimed at delivering differentiated therapies to patients. She is a strategic thinker with superior ability to link preclinical approaches to clinical development.
celine pallaud
16:00 – 17:00
Drinks/Canape Reception

Partners

Immuno-Oncology Xchange | Europe 2023
Register